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T5:PS3 – CO-MORBIDITIES, INCLUDING DIABETES
(-0.8 ± 0.5 vs. -0.9 ± 0.7 points). Decrease in voiding score was signifi-
cantly associated with weight (r = 0.36, p = 0.01) and HOMA (r = 0.42, 
p<0.01). In the MR group, reduction in storage symptom score was 
greater than the CD group (-1.6 ± 1.3 vs -1.0 ± 0.8 points), and correlat-
ed (r = 0.50, p = 0.02) with greater reduction in saturated fat intake.
Conclusion: Meal replacement-based diets are effective for improving 
voiding and storage LUTS by reducing insulin resistance and fat intake.  
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Introduction: There are reports showed that visfatin levels increase 
with obesity, diabetes mellitus (DM) and gestational diabetes (GDM).  
This evidence suggests that visfatin can be stimulated under a hypergly-
cemic environment. It seems that elevated visfatin concentration in 
T2DM may be a physiologic protective response to a hyperglycemic
environment. The aim of the study was to compare levels of visfatin, 
adiponectin, glucose tolerance parameters and anthropometric measure-
ments between obese women with normal and impaired glucose toler-
ance.
Methods: Twenty four obese women with newly diagnosed impaired 
glucose tolerance (IGT group) and fifty obese normoglycemic women 
(control group) were recruited in our study (IGT group mean age: 
40.1±9.9 yr, mean BMI=35.6±4.8 kg/m2 vs. control group: mean age 
37.3±10.5 yr, mean BMI=36.0±5.0 kg/m2). We measured fasting insulin, 
plasma glucose, HOMA-IR, AUC insulin (2h OGTT), fasting adiponec-
tin and fasting visfatin level and anthropometric parameters (BMI and 
waist).
Results: Fasting visfatin (ng/ml) levels were statistically significantly 
higher in IGT group compared to control group (58.42=/-8.23 
vs.25.45+/-2.21, p<0.05). A significant difference in HOMA-IR (6.45+/-
0.93 vs. 4.57+/-0.36, p<0.05) between IGT and control group was de-
tected.  Statistically significant difference in fasting adiponectin, AUC 
insulin, BMI and waist were not detected. Adiponectin was negatively 
correlated with HOMA-IR in control group (p<0.001), but not in IGT 
group. There was no statistically significant correlation between fasting 
visfatin levels and HOMA-IR in both of these two groups.
Conclusion: Fasting plasma visfatin is elevated in women with im-
paired glucose tolerance, but physiological mechanism on how visfatin 
affects insulin resistance still remains unclear.
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Introduction: Weight management is challenging in medically complex 
patients with obesity. 
Methods: We retrospectively analysed medically complex obese pa-
tients entering 16 week intensive weight management programme 
(IWMP) at our Hospital between January 2012 and July 2012. The 
programme consists of 8 weeks of a low energy liquid diet (1000–1200 
Kcal/d) followed by meal replacement. A close medical supervision, 
complex dietary and behaviour support were provided. Participants’ 
comorbid state was staged from 0 to 4 according to the Edmonton Obe-
sity Scoring System1 (EOSS) reflecting complex nature of the cases. 
Results: Eighteen of 23 patients completed the programme. Baseline 
characteristics were body weight 131.9 ± 23.6 kg (mean ± SD) (range 
99–178.6 Kg), BMI 43.7±8.2 kg/m2 (range 37.2–67.8), 13 females, age 
(49.6±13.3 (range 18–75), number of comorbidities 4.1±1.8 (1 to 7), 
EOSS score 1.94±0.64, median 2 (1 to 3). Patients include Diabetes 
(57%) of those 6 (26%) were on insulin, Chronic kidney disease stage 3 
or above (13%), heart failure (17%), sleep apnoea (30%), hypertension 
(65%) and of those 4 (17%) were on 3 or more antihypertensive, hypo-
pituitarinism (13%), osteoarthritis (17%). Mean weight change at week 
16 was -11.8 kg (9.0% [-27.2 kg to -2.1 kg]). Insulin requirements 
dropped on average by 27.3% (n=5, no data on 1 drop out) and antihy-
pertensive requirements reduced from a median of 1 to 0 (n=9). 
Conclusion: Patients with complex medical comorbidities were able to 
lose weight effectively and safely under close supervision, furthermore 
weight loss is associated with advantageous changes in the use of anti-
diabetic and antihypertensive medications.  
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Introduction: Obesity can coexist with several endocrine disorders, 
including Cushing's syndrome (CS). Their exclusion is essential before 
obesity surgical treatment. Although CS is characterized by a broad 
spectrum of clinical manifestations, a significant number of patients 
present only with simple obesity. 
Objectives: To determine the frequency of CS in an obese population. 
Methods: Cross-sectional study of a population of 398 obese adults 
evaluated at the first attendance of Multidisciplinary Assessment of 
Surgical Treatment of Obesity. A first CS screening step was performed 
with 24h-urinary free cortisol (UFC). A second confirmatory step in-
volved 1mg overnight dexametasone supression test (1 mg-DST). CS 
diagnosis was confirmed by 48-h, 2 mg/d low-dose DST (LDDST) and 
differential diagnosis by high-dose DST (HDDST), ACTH and imaging 
studies. 
Results: 336 (84.4%) were female and 62 (15.6%) were male, with a 
mean age of 41.3±10.9 years and a median BMI of 42 kg/m2 (IQR 40.7-
47.6). UFC was increased in16 (4%). UFC was positively correlated 
with BMI (r = 0.194, p <0.01). 49 patients with clinical signs of CS or 
increased UFC performed 1mg-DXM: 8 patients had last cortisol >1.8 
ug / dL; two tests were simultaneously positive in 3 patients, in whom 
CS was confirmed. CS was diagnosed in another patient with an UFC of 
31.5 ug / dL, but last cortisol of 9.8 ug / dL after LDDST.
Conclusions: CS was confirmed in 4 patients, which gives a prevalence 
of 1%. There was a statistically significant positive correlation between 
BMI and UFC.
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